Latest Earnings Results: Q1 '26
Estimated EPS
-$0.11
Reported EPS
---
Surprise
---
Estimated Rev
$59.3M
Reported Rev
---
Surprise
---
$DAWN Q4 '25 Earnings Results & Recap • Reported GAAP EPS of -$0.21 up 69.57% YoY • Reported revenue of $53.72M up 83.92% YoY • Day One Biopharmaceuticals expects to complete enrollment of the pivotal Phase 3 FIREFLY-2 trial, evaluating tovorafenib as a front-line therapy in pLGG, in the first half of 2026.
Generated by Stocktwits using AI and company-reported earnings data for Q1 '26. This recap is intended to help readers understand the quarter quickly. Verify key figures in the linked source materials; the summary may contain errors and is not investment advice.
Historical Earnings
Quarterly
Annual
EPS
Revenue
| Fiscal Period | Estimated | Reported | Surprise | Result |
|---|---|---|---|---|
Q2 '26 | -$0.10 | -- | -- | N/A |
Q1 '26 | -$0.11 | -- | -- | N/A |
Q4 '25 | -$0.15 | -$0.21 | -41.06% | MISSED |
Q3 '25 | -$0.30 | -$0.19 | 36.00% | BEAT |
Q2 '25 | -$0.36 | -$0.29 | 18.66% | BEAT |